Adjuvant treatment with Imatinib is the standard of care for high-risk resected GISTs. Imatinib is known to have an impact on bone mineral density in patients affected by chronic myeloid leukemia, however this effect has never been investigated in GISTs.

We retrospectively evaluated, on CT scans, the effect of adjuvant Imatinib (400 mg/die) on bone mineral density and muscle composition in 14 patients with surgically resected GISTs and in a control group of 8 patients who did not received any treatment. The effect of bone and muscle composition on Imatinib-tolerance was assessed as well.

Overall patients receiving Imatinib experienced an increase in bone mineral density during treatment (p = 0.021); with higher increase in patients with basal values < 120 mg/cm³ (p = 0.002). No changes were observed in the control group (p = 0.918).

Skeletal muscle index and lean body mass did not change over time during Imatinib therapy; however, patients with lower lean body mass and lower body mass index experienced more grade 3 treatment related toxicities (p = 0.024 and p = 0.014 respectively). We also found a non-significant trend between basal BMD and grade 3 toxicities (p = 0.060)

伊马替尼的辅助治疗是高危切除 GIST 的护理标准。已知伊马替尼对慢性粒细胞白血病患者的骨矿物质密度有影响，但这种影响从未在 GIST 中进行过研究。

我们在 CT 扫描中回顾性评估了辅助伊马替尼（400 mg/die）对 14 名手术切除 GIST 患者和 8 名未接受任何治疗的对照组患者的骨矿物质密度和肌肉成分的影响。还评估了骨骼和肌肉成分对伊马替尼耐受性的影响。

接受伊马替尼的总体患者在治疗期间经历了骨矿物质密度的增加（p = 0.021）；^{基础值 < 120 mg/cm 3}的患者增加较多（p = 0.002）。对照组没有观察到变化（p = 0.918）。

在伊马替尼治疗期间，骨骼肌指数和瘦体重不随时间变化；然而，瘦体重和体重指数较低的患者经历了更多的 3 级治疗相关毒性（分别为 p = 0.024 和 p = 0.014）。我们还发现基础 BMD 和 3 级毒性之间的趋势不显着（p = 0.060）